ACADIA Pharmaceuticals Inc.
Exchange: IEX Type: Common Stock
Price at Close
Change:
Volume:
×
Buy Stock
Remote Buying of ACADIA Pharmaceuticals Inc. through IEX is under development on ETFS.com.
Notify Me when it is ready×
Sell Stock
Remote Selling of ACADIA Pharmaceuticals Inc. through IEX is under development on ETFS.com.
Notify Me when it is ready
Key Statistics
- Open
- Previous Close
- Bid
- Ask
- Day Range -
- 52 Week Range -
- Volume
- Avg. Volume
- Volume to USD
- Market Cap
- Beta
- PE Ratio
- Latest EPS
- EPS TTM
- Dividend
- Dividend Yield
- Ex-Dividend Date
- Revenue TTM
- Revenue per Share
- Revenue per Employee
- Profit Margin
- Gross Profit TTM
- Total Cash TTM
- Total Debt TTM
Share Distribution
- Shares Outstanding
- Float
- Short Interest
- Short Ratio
- Insider Ownership
- Institution Ownership
Latest Headlines
Galmed Pharmaceuticals downgraded to neutral from buy at B. Riley FBR via MarketWatch
Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q1 2020 Results - Earnings Call Transcript via Seeking Alpha
ACADIA Pharmaceuticals Inc. Performance
Active Alerts for IEX:ACAD
You don't have any alerts set for IEX:ACAD.
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Real-time ACAD to USD Trade Analysis on IEX
Market Status Closed
Analysis is available when the exchange & market are open.